This course has expired. View available courses.
Endocrinology
Moving forward towards better control: Reaching diabetes targets by reducing therapeutic inertia
Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.
DURATION
1 hr
PROFESSION
Physician
# OF CREDITS
1
ACCREDITATION
Mainpro+
EXPIRY DATE
2023-01-22
Type 2 diabetes is a progressive condition in which intensification of therapy will be required to maintain glycemic control. Current Diabetes Canada clinical practice guidelines recommend adjustment and intensification of antihyperglycemic therapy to reach A1C targets within 3 to 6 months. Chart audits have shown that it is common for diabetes patients not to be offered changes in pharmacotherapy when their A1C is above target. The COVID-19 pandemic has likely worsened this situation. This program will provide clinicians with an approach to better address resistance to intensification and therapeutic inertia with practical recommendations that can be integrated into practice.
This program has received an unrestricted educational grant or in-kind support from IQVIA.
Faculty
Maureen Clement, MD, CFPC
Jeffrey Habert, MD, CFPC, FCFP
Noah Ivers, MD, PhD, CFPC
James Kim, MBBCh, PgDip
Learning objectives
Upon completion of this continuing education program participants will be better able to:
- Define therapeutic inertia and its impact on people living with type 2 diabetes
- Review the role of patients, clinicians and the healthcare system in therapeutic inertia
- Determine strategies to reduce therapeutic inertia in practice
- Apply therapeutic inertia strategies to clinical cases